Nkarta, Inc.
NASDAQ:NKTXBiotechnology
+$0.09 today
- Market cap
- $82.37M
- Beta
- 0.90
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$1.35
Volume 0.81M
Average 0.75M
NKTX Interest Income
Income earned on cash, deposits, and investments held by the company.
Nkarta, Inc.NASDAQ: NKTX
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income declines year over year
Q1 FY2026 interest income of $2.84M fell 35.1% year over year, behind the -31.7% change in trailing-twelve-month interest income. Sequentially, it fell 13.9% from the prior quarter. Over 3 fiscal years it compounded at +40.5% a year.
Context
- Interest income increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -35.1% toward the trailing-twelve-month pace of -31.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 15.49M USD
- Year-over-year change
- -19.8%
- 4-year CAGR
- +154.4%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.49M | -19.8% |
| FY2024 | 2024-12-31 | 19.32M | +36.9% |
| FY2023 | 2023-12-31 | 14.11M | +152.5% |
| FY2022 | 2022-12-31 | 5.59M | +1410.3% |
| FY2021 | 2021-12-31 | 370K | — |
Interest Income vs competitors
How NKTX compares with its peers on the latest reported figures
- Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -31.7% is the 3rd highest of 7, against a peer median of -39.2%.
- Over three fiscal years its annual growth of +40.5% compares with a peer median of +23.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $13.96M USD | -31.7% | +40.5% | — | |
| LTM Mar 2026 | $9.58M USD | -41.8% | +23.7% | 151.7% | |
| LTM Mar 2026 | $9M USD | +153.2% | +64.3% | — | |
| LTM Mar 2026 | $4.15M USD | -36.5% | +12.9% | — | |
| LTM Mar 2026 | CHF 1.48M CHF | -47.8% | +8.4% | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $723K USD | -13.6% | +128.8% | — |
| LTM Mar 2026 | $0 USD | -100.0% | — | — | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding NKTX) | — | -39.2% | +23.7% | 75.9% | |
Competitors are the stored peer set for NKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 5.87M | 0 | 9.19M |
| Gross Profit | 0 | 0 | (5.87M) | 0 | (9.19M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 63.41M | 90.9M | 90.9M | 96.74M | 90.43M |
| Selling, General & Admin | 23.02M | 28.06M | 34.88M | 31.45M | 31.57M |
| Operating Expenses | 86.43M | 118.96M | 125.78M | 128.19M | 112.01M |
| Depreciation & Amortization | 1.76M | 2.64M | 5.87M | 9.15M | 9.19M |
| EBITDA | (84.32M) | (105.61M) | (120.48M) | (99.64M) | (94.89M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (86.43M) | (118.96M) | (131.65M) | (128.19M) | (121.21M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 370K | 5.59M | 14.11M | 19.32M | 15.49M |
| Interest Expense | 0 | 5.59M | 0 | 0 | 0 |
| Other Income / Expenses | 354K | 5.12M | 14.15M | 19.4M | 17.12M |
| Income Before Tax | (86.08M) | (113.84M) | (117.5M) | (108.79M) | (104.08M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (86.08M) | (113.84M) | (117.5M) | (108.79M) | (104.08M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.62) | (2.61) | (2.40) | (1.60) | (1.41) |
| EPS (Diluted) | (2.62) | (2.61) | (2.40) | (1.60) | (1.41) |
| Weighted Avg Shares | 32.86M | 43.63M | 49.01M | 67.87M | 73.99M |
| Weighted Avg Shares (Diluted) | 32.86M | 43.63M | 49.01M | 67.87M | 73.99M |
Nkarta, Inc.
NASDAQ:NKTX
Intrinsic Alpha fair value
Locked
Current Price
$1.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.